AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18004129 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg/d for 1 week then 200 mg/d for 6 weeks)
Number of subjects: 73
Study 18004129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 6 weeks)
Number of subjects: 73
Study 15012923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Imaging (THI)
Number of subjects: 31
Study 15012923 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Opacification (LVO)
Number of subjects: 31
Study 15012923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental imaging
Number of subjects: 31
Study 15012923 — intervention group
Group type: EXPERIMENTAL
Intervention: LVO with ECG-triggered Power Doppler
Number of subjects: 31
Study 15012923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 31
Study 12468952 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (n = 10)
Number of subjects: 26
Study 12468952 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy (n = 8)
Number of subjects: 26
Study 12468952 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide injection (n = 8)
Number of subjects: 26
Study 9801509 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Path for Coronary Artery Bypass Graft Patients
Number of subjects: 0
Study 9801509 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study 7698703 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 0
Study 2535052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosenopril
Number of subjects: 18
Study 2535052 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 18
Study 380868 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen, 500 mg/day for 1 week
Number of subjects: 14
Study 380868 — intervention group
Group type: COMPARATOR
Intervention: diclofenac, 100 mg/day for 1 week
Number of subjects: 14
Study 31101782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 15 mg/kg/day for 12 months
Number of subjects: 0
Study 31101782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 mg/day plus Vitamin C 500 mg/day for 12 months
Number of subjects: 0
Study 31101782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medical treatment)
Number of subjects: 0
Study 28710212 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week internet intervention (Deprexis) plus usual care
Number of subjects: 1013
Study 28710212 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual alone (control)
Number of subjects: 1013
Study 25329141 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage focused on myofascial trigger points (MTrPs)
Number of subjects: 56
Study 25329141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (detuned ultrasound)
Number of subjects: 56
Study 25329141 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 56
Study 23410808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg monthly intravitreal injection)
Number of subjects: 0
Study 23410808 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (quarterly intravenous verteporfin coupled with PDT)
Number of subjects: 0
Study 22494532 — intervention group
Group type: EXPERIMENTAL
Intervention: Soothing music for 45 min at nocturnal sleep time
Number of subjects: 50
Study 22494532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music exposure)
Number of subjects: 50
Study 19406542 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-Pump Coronary Artery Bypass Surgery (OPCAB)
Number of subjects: 27806
Study 19406542 — intervention group
Group type: COMPARATOR
Intervention: Conventional CAB (CAB)
Number of subjects: 27806
Study 17550932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoguanidine (iNOS inhibitor)
Number of subjects: 16
Study 17550932 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 16
Study 15531222 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic coeliac plexus blockade (NCPB)
Number of subjects: 39
Study 15531222 — intervention group
Group type: COMPARATOR
Intervention: Bilateral splanchnic nerve blockade (SNB)
Number of subjects: 39
Study 11797066 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg
Number of subjects: 20
Study 11797066 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 20
Study 11797066 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 20
Study 9492128 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (first injection)
Number of subjects: 50
Study 9492128 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (second injection)
Number of subjects: 50
Study 7952396 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical limb perfusion
Number of subjects: 0
Study 7952396 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3139830 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (20 mg)
Number of subjects: 15
Study 3139830 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg) after 30-day therapy
Number of subjects: 15
Study 3139830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31768589 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily TPTD (20-μg injection daily for 6 months)
Number of subjects: 13
Study 31768589 — intervention group
Group type: COMPARATOR
Intervention: Weekly TPTD (56.5-μg injection 1×/week for 6 months)
Number of subjects: 13
Study 28687150 — intervention group
Group type: COMPARATOR
Intervention: Virtually optimized insoles (milled)
Number of subjects: 20
Study 28687150 — intervention group
Group type: COMPARATOR
Intervention: Virtually optimized insoles (printed)
Number of subjects: 20
Study 28687150 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape-based devices
Number of subjects: 20
Study 26096691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (6 mg)
Number of subjects: 62
Study 26096691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 23293012 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg amitriptyline
Number of subjects: 32
Study 23293012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23293012 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 32
Study 21226792 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes screening intervention
Number of subjects: 3240
Study 18433307 — intervention group
Group type: EXPERIMENTAL
Intervention: MRK adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine (3-dose regimen, doses ranging from 3 x 10^6 to 1 x 10^11 viral particles per 1-mL dose)
Number of subjects: 259
Study 18433307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 17294878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle training (BT) with free choice of load parameters (FLC)
Number of subjects: 185
Study 17294878 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital treatment
Number of subjects: 185
Study 14611708 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (85.5 +/- 4.3 microg/d)
Number of subjects: 66
Study 14611708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 11938802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal treatment added during prednisone reduction
Number of subjects: 120
Study 11938802 — intervention group
Group type: COMPARATOR
Intervention: Prednisone treatment (control group)
Number of subjects: 120
Study 9104548 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 12 weeks
Number of subjects: 214
Study 9104548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 8478303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg/day orally once daily for 10-14 days
Number of subjects: 173
Study 8478303 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 1000 mg/day orally four times daily for 10-14 days
Number of subjects: 173
Study 3522452 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg)
Number of subjects: 6
Study 3522452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study 30051366 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions for rectal cancer
Number of subjects: 130
Study 26247163 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious Electrical Stimulation (NES)
Number of subjects: 40
Study 26247163 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Contractions
Number of subjects: 40
Study 26247163 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Cycling
Number of subjects: 40
Study 23837549 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Current (CC) stimulation
Number of subjects: 30
Study 23837549 — intervention group
Group type: COMPARATOR
Intervention: Constant Voltage (CV) stimulation
Number of subjects: 30
Study 23402179 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifiform (Bifidobacterium longum 10^7 and Enterococcus faecium 10^7) for 14 days
Number of subjects: 138
Study 23402179 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 138
Study 20581391 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (target dose, 2 mg daily)
Number of subjects: 100
Study 20581391 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 100
Study 18766092 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time audiovisual feedback during the second and third trials
Number of subjects: 80
Study 18766092 — intervention group
Group type: COMPARATOR
Intervention: Debriefing only (no feedback)
Number of subjects: 80
Study 18766092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of feedback and debriefing
Number of subjects: 80
Study 16389536 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback + academic detailing
Number of subjects: 1800
Study 16389536 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback + seminar
Number of subjects: 1800
Study 16389536 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback alone
Number of subjects: 1800
Study 16389536 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1800
Study 12895205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline
Number of subjects: 57
Study 12895205 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 57
Study 12895205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 10848884 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance tests (ITT) performed during menstrual cycle phases in women
Number of subjects: 12
Study 10848884 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance tests (ITT) performed in men
Number of subjects: 12
Study 9112525 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh length pneumatic compression
Number of subjects: 90
Study 9112525 — intervention group
Group type: COMPARATOR
Intervention: Calf length pneumatic compression
Number of subjects: 90
Study 1549432 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulus pulses audible (synchronization)
Number of subjects: 0
Study 1549432 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulus pulses turned off (continuation)
Number of subjects: 0
Study 2581075 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 30 mg
Number of subjects: 6
Study 2581075 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 60 mg
Number of subjects: 6
Study 2581075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31783881 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSOFA score on day 7
Number of subjects: 647
Study 31783881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean SOFA score on day 1
Number of subjects: 647
Study 31783881 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day mortality
Number of subjects: 647
Study 28849703 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Memory Questionnaire (EMQ)
Number of subjects: 169
Study 27085221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler (OD) monitoring
Number of subjects: 67
Study 27085221 — intervention group
Group type: COMPARATOR
Intervention: Standard parameters (Standard group)
Number of subjects: 67
Study 27085221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 25076013 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg quercetin
Number of subjects: 15
Study 25076013 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg quercetin
Number of subjects: 15
Study 25076013 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 15
Study 25076013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25076013 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin and isorhamnetin
Number of subjects: 15
Study 25076013 — intervention group
Group type: EXPERIMENTAL
Intervention: Q3GA
Number of subjects: 15
Study 22646692 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric syndrome complications (≥ 2 complications)
Number of subjects: 350
Study 22646692 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric syndrome complications (one complication)
Number of subjects: 350
Study 22646692 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric syndrome complications (no complications)
Number of subjects: 350
Study 22646692 — intervention group
Group type: EXPERIMENTAL
Intervention: Unresolved geriatric syndrome complications
Number of subjects: 350
Study 22646692 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolved geriatric syndrome complications
Number of subjects: 350
Study 20205025 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion campaigns targeting Theory of Reasoned Action (TRA)‐based predictors of condom use
Number of subjects: 756
Study 17604555 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening (specific music tasks)
Number of subjects: 266
Study 17604555 — intervention group
Group type: EXPERIMENTAL
Intervention: Music of Nolwenn Leroy
Number of subjects: 266
Study 17604555 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening tasks
Number of subjects: 266
Study 17604555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music listening)
Number of subjects: 266
Study 15207544 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphiphilogels
Number of subjects: 0
Study 15207544 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium lauryl sulphate (SLS) solution
Number of subjects: 0
Study 15207544 — intervention group
Group type: COMPARATOR
Intervention: Aqueous Cream BP
Number of subjects: 0
Study 11794914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory management for GDM
Number of subjects: 681
Study 11794914 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization for GDM
Number of subjects: 681
Study 11794914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory management for PGDM
Number of subjects: 681
Study 11794914 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization for PGDM
Number of subjects: 681
Study 11794914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory management
Number of subjects: 681
Study 11794914 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 681
Study 9919007 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV positive patients (22 out of 55, 40%)
Number of subjects: 55
Study 9919007 — intervention group
Group type: COMPARATOR
Intervention: ELISA for HCV detection
Number of subjects: 55
Study 9919007 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR for HCV detection
Number of subjects: 55
Study 8042098 — intervention group
Group type: EXPERIMENTAL
Intervention: More expensive nebulisers (Eolo, Pharmoneb, Pari)
Number of subjects: 6
Study 8042098 — intervention group
Group type: COMPARATOR
Intervention: Cheaper nebulisers (Simba, New Constellation, Ariette)
Number of subjects: 6
Study 8042098 — intervention group
Group type: EXPERIMENTAL
Intervention: All nebuliser models
Number of subjects: 6
Study 8042098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulisers (various models)
Number of subjects: 6
Study 3051071 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 62
Study 3051071 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 62
Study 3051071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3051071 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MAO activity
Number of subjects: 62
Study 31221002 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 37
Study 31221002 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 37
Study 27461413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum messages
Number of subjects: 598
Study 27461413 — intervention group
Group type: COMPARATOR
Intervention: Categorical messages
Number of subjects: 598
Study 27461413 — intervention group
Group type: COMPARATOR
Intervention: Neutral control messages
Number of subjects: 598
Study 26133711 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg/kg of DEX
Number of subjects: 80
Study 26133711 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 80
Study 23475383 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic tasks with head restrained or free to move
Number of subjects: 5
Study 23475383 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-free condition
Number of subjects: 5
Study 23475383 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 5
Study 21772315 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine in sugar-sweetened beverages (SSBs)
Number of subjects: 93
Study 21772315 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of caffeine from SSBs
Number of subjects: 93
Study 19164403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital exercise programme
Number of subjects: 32
Study 19164403 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme
Number of subjects: 32
Study 19164403 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hospital vs home exercise programme
Number of subjects: 32
Study 16618363 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic formula (0.6 g GOS/FOS/100 ml)
Number of subjects: 57
Study 16618363 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formula (6.0 x 10^9 cfu Bifidobacterium animalis/100 ml)
Number of subjects: 57
Study 16618363 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 57
Study 14744166 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 60 mg/day
Number of subjects: 150
Study 14744166 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine 300 mg/day
Number of subjects: 150
Study 14744166 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to alternate SRI (either paroxetine or venlafaxine) after 4-week tapering phase
Number of subjects: 150
Study 11735135 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 435
Study 11735135 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 435
Study 11735135 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (unilateral procedures)
Number of subjects: 435
Study 9425967 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge Quincke type needle
Number of subjects: 400
Study 9425967 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge pencil-point needle
Number of subjects: 400
Study 9425967 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of postdural puncture headache
Number of subjects: 400
Study 8276300 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation combined with intraperitoneal instillation of radioactive gold (198Au)
Number of subjects: 253
Study 8276300 — intervention group
Group type: COMPARATOR
Intervention: External irradiation alone
Number of subjects: 253
Study 8276300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal radioactive therapy followed by thio-TEPA
Number of subjects: 253
Study 8276300 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 253
Study 8276300 — intervention group
Group type: EXPERIMENTAL
Intervention: Thio-TEPA
Number of subjects: 253
Study 8276300 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 253
Study 8276300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 253
Study 8276300 — intervention group
Group type: COMPARATOR
Intervention: 32P treatment
Number of subjects: 253
Study 3320784 — intervention group
Group type: EXPERIMENTAL
Intervention: bendrofluazide
Number of subjects: 17354
Study 3320784 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 17354
Study 3320784 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17354
Study 31083170 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention program (6 sessions, once weekly)
Number of subjects: 160
Study 28089730 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic inflammation
Number of subjects: 4099
Study 28089730 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inflammation
Number of subjects: 4099
Study 28089730 — intervention group
Group type: COMPARATOR
Intervention: No intervention (placebo group)
Number of subjects: 4099
Study 24685604 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based high frequency exercise (HFE) - aerobic exercise at 70% of max for 30 minutes, five times/week and resistance exercise three times/week for eight weeks
Number of subjects: 62
Study 24685604 — intervention group
Group type: COMPARATOR
Intervention: Control group - usual lifestyle
Number of subjects: 62
Study 24685604 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based high frequency exercise (HFE)
Number of subjects: 62